847728-01-2
847728-01-2
Chemical Structure
CJ-42794
Synonym(s): CJ-042794
- CAS No.: 847728-01-2
- Formula:C22H17ClFNO4
- Molecular Weight:413.83
IUPAC Name: (S)-4-(1-(5-chloro-2-(4-fluorophenoxy)benzamido)ethyl)benzoic acid
InChIKey: MWBNCZHVEXULBD-ZDUSSCGKSA-N
SMILES: ClC1=CC=C(OC2=CC=C(F)C=C2)C(C(N[C@H](C3=CC=C(C(O)=O)C=C3)C)=O)=C1
Biological Activity: CJ-42794 (CJ-042794) is a potent, orally active, selective prostaglandin E receptor 4 (EP4) antagonist with an IC50 value of 10 nM, which is 200-fold more selective than EP1, EP2 and EP3. CJ-42794 can be used in research of gastric ulcers[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CJ-42794 | 98.53% | CJ-42794 (CJ-042794) is a potent, orally active, selective prostaglandin E receptor 4 (EP4) antagonist with an IC50 value of 10 nM, which is 200-fold more selective than EP1, EP2 and EP3. CJ-42794 can be used in research of gastric ulcers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CJ-42794 (Standard) | ≥98% | CJ-42794 (Standard) is the analytical standard of CJ-42794 (HY-10797). This product is intended for research and analytical applications. CJ-42794 (CJ-042794) is a potent, orally active, selective prostaglandin E receptor 4 (EP4) antagonist with an IC50 value of 10 nM, which is 200-fold more selective than EP1, EP2 and EP3. CJ-42794 can be used in research of gastric ulcers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Murase A, et, al. In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist. Life Sci. 2008 Jan 16;82(3-4):226-32. [Content Brief]
- [2]. Takeuchi K, et, al. Effect of (S)-4-(1-(5-chloro-2-(4-fluorophenyoxy)benzamido)ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa. J Pharmacol Exp Ther. 2007 Sep;322(3):903-12. [Content Brief]
Keywords
